Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (Date of earliest event reported) March
6, 2006
Interpharm
Holdings, Inc.
(Exact
name of Registrant as specified in charter)
Delaware
|
0-22710
|
13-3673965
|
(State
or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
|
|
75
Adams Avenue, Hauppauge, New York 11725
(Address
of principal executive offices)
(Zip
Code)
Registrant's
telephone number, including area code: (631)
952-0214
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
oWritten
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting
material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR240.14d-2(b))
oPre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02 Departure
of Directors or Principal Officers; Election of Directors;
Appointment of
Principal Officers
Effective
March 6, 2006, Dr. Mark A. Goodman resigned from his position as a member of
the
registrant’s Board of Directors.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
INTERPHARM
HOLDINGS, INC.
|
|
|
|
March
8, 2006
|
By: |
/s/
George
Aronson
|
|
George
Aronson
|
|
Chief
Financial Officer
|
Exhibits
Exhibit
17 |
Letter
from Dr. Mark A. Goodman M.D. dated March 6, 2006 |
|
|
|
|
|
|
|
|